Rallybio Corp (NASDAQ: RLYB) is a clinical-stage biopharmaceutical company focused on developing product candidates for rare and severe diseases. The company generates no product revenue and finances operations through equity sales, debt financings, collaborations, strategic alliances, and licensing arrangements, as disclosed in its 10-K filed March 16, 2026. As of FY2025, net cash used in operating activities was $29.8 million, down from $49.3 million in FY2024, reflecting reduced research and development and general and administrative spending. Investing activities provided $47.3 million in FY2025, primarily from maturities of highly-rated securities. Rallybio has limited financial resources and has concentrated development on a select set of product candidates. The company is incorporated in Delaware and led by Stephen Uden, M.D. as Chief Executive Officer and President, with Jonathan I. Lieber, M.B.A. as Chief Financial Officer and Steven Ryder, M.D. as Chief Medical Officer. As of the filing date, Rallybio had entered into a merger agreement with Candid, with pre-merger Rallybio equityholders expected to own approximately 3.65% of the combined company upon closing.

Revenue model

No product revenue as of the 10-K filed March 16, 2026. Operations are financed through equity issuances, debt financings, collaborations, strategic alliances, and licensing arrangements. The company holds no committed external funding source.

Products and services

Clinical-stage product candidates targeting rare and severe diseases. Specific product names are not detailed in the provided filing excerpts.

Customers and end markets

No commercial customers as of the filing date. Target end markets are patients with rare and severe diseases, subject to U.S. FDA approval and government reimbursement programs including Medicare and Medicaid.

Value-chain role

Pre-commercial drug developer. Conducts research and clinical development internally, with no disclosed manufacturing or commercial sales infrastructure. Subject to FDA and analogous international regulatory oversight.

Geographic exposure

Primary operations in the United States. Subject to GDPR and UK GDPR data protection requirements, indicating some exposure to European regulatory frameworks.

Source: SEC 10-K, filed 2026-03-16

Industry: Pharmaceutical Preparations Peers: ADMA Biologics Inc Alaunos Therapeutics Inc Allakos Inc. Aura Biosciences Inc C4 Therapeutics, Inc Entrada Therapeutics Inc Inovio Pharmaceuticals Inc Precigen Inc Lexicon Pharmaceuticals Inc